Term Sheet

The latest on private equity, M&A, deals and movements — from Wall Street to Silicon Valley

How much does SV Life Sciences really plan to raise?

January 16, 2014: 3:26 PM ET

sv-life-sciencesHealthcare VC firm prepares to raise its next fund.

FORTUNE -- Earlier this week, Dow Jones reported that SV Life Sciences is targeting $525 million for its sixth healthcare-focused venture capital fund. Well, sort of.

First, the Boston-based firm isn't fundraising yet. That won't happen until the second half of 2014.

If things go well, it is entirely possible that SV Life Sciences will tie off the fund at $525 million -- as it did for its fifth fund in 2009. But both Fund V and the $572 million Fund IV (raised in 2005) actually were marketed with $400 million targets.

Apparently SV Life Sciences views $400 million as the minimum amount it can raise and still execute against its strategy. Plus, it doesn't hurt from a PR perspective to set expectations low and then talk about being "oversubscribed."

Sign up for Dan Primack's daily email newsletter on deals and deal-makers: GetTermSheet.com

Join the Conversation
About This Author
Dan Primack
Dan Primack
Senior Editor, Fortune

Dan Primack joined Fortune.com in September 2010 to cover deals and dealmakers, from Wall Street to Sand Hill Road. Previously, Dan was an editor-at-large with Thomson Reuters, where he launched both peHUB.com and the peHUB Wire email service. In a past journalistic life, Dan ran a community paper in Roxbury, Massachusetts. He currently lives just outside of Boston.

Email a Tip | @danprimack | RSS
Current Issue
  • Give the gift of Fortune
  • Get the Fortune app
  • Subscribe
Powered by WordPress.com VIP.